ARTICLE | Clinical News
Alirocumab: Phase III data
January 12, 2015 8:00 AM UTC
Top-line data from the double-blind, international Phase III ODYSSEY CHOICE I and CHOICE II trials in patients with hypercholesterolemia showed that subcutaneous alirocumab every 4 weeks met the prima...